Why Is There An Increased Risk Of Severe Adverse Perinatal Outcomes After The Use Of Clomiphene Citrate For Infertility Treatment?
Funder
National Health and Medical Research Council
Funding Amount
$570,065.00
Summary
Clomiphene citrate (CC) has been a first line treatment for female infertility internationally since the 1960’s. However, safety studies using routine prescribing practices were never performed, and numerous data sources now indicate that CC is associated with major adverse outcomes if the fetus is inadvertently exposed. We are linking prescription data to perinatal outcomes to confirm how CC is associated with adverse events so as to inform prescriber and practice change.
The Ovarian Cancer Prognosis And Lifestyle (OPAL) Study: Long-term Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$871,657.00
Summary
Ovarian cancer affects 1500 women each year in Australia and 5-year survival is <45%. Affected women thus face a poor prognosis and often ask what they can do to improve this. There is no direct evidence whether a woman’s lifestyle might influence her outcomes, although data from breast cancer suggest this is possible. The OPAL Study is following 960 women with ovarian cancer to identify whether lifestyle is associated with long-term survival to provide evidence for women with this disease.
Improving Outcomes From Ovarian Cancer: Building The Evidence To Help Women Help Themselves
Funder
National Health and Medical Research Council
Funding Amount
$1,839,772.00
Summary
Ovarian cancer affects 1300 women each year in Australia and 5-year survival is <45%. Women with this cancer thus face a poor prognosis and many ask what they can do to improve this. There is no direct evidence whether a woman’s lifestyle might influence her outcomes, although data from breast cancer suggest this is possible. The OPAL Study will follow 1200 women with ovarian cancer to identify whether lifestyle is associated with survival to provide guidance for women with this disease.
Ovarian and endometrial cancer affect >3,200 women each year in Australia and 3 or 4 women die from these cancers every day. The overall aim of my program of research is to reduce the burden of these cancers in future generations of Australian women by increasing our understanding of (i) what causes them, (ii) how we can optimise patient management to enhance patient outcomes and (ii) how lifestyle changes might improve quality and life and survival, for women who are diagnosed with them.